

# STEM CELL

M E E T I N G   O N   T H E   M E S A

## *3rd Annual* Stem Cell Meeting on the Mesa

Friday, November 7th, 2008

The Frederic de Hoffmann Auditorium

The Salk Institute for Biological Studies

San Diego, California

*Presented by*



*Lead Sponsor*



## 2008 Keynote Speaker



### **Kenneth R. Chien, M.D., Ph.D.**

Director, MGH Cardiovascular Research Center  
Charles Addison and Elizabeth Ann Sanders, Professor,  
Department of Cell Biology, HMS  
Harvard Stem Cell Institute

Dr. Kenneth Chien is an internationally recognized biologist specializing in cardiovascular science, as well as a pioneer in developing new therapeutic strategies to prevent the onset and progression of heart failure. Since July 2005, he has returned to Boston as Scientific Director of the Cardiovascular Research Center at Massachusetts General Hospital and Professor of Cell Biology at Harvard Medical School. He is a member of the Harvard Stem Cell Institute, where he leads the university-wide Cardiovascular Stem Cell Biology Program. Upon his return to the Harvard community, he was awarded the distinction of the first endowed chair of the Charles Addison & Elizabeth Ann Sanders Professor of Medicine. Prior to his MGH/HMS appointments, Dr. Chien directed the Institute for Molecular Medicine at the University of California at San Diego (UCSD). He is a professor emeritus at UCSD, and continues his appointment as an adjunct professor of The Salk Institute.

A graduate of Harvard University, Dr. Chien went on to earn his MD and PhD from Temple University in Pennsylvania. After completing his internship, residency, and cardiology fellowship training at the University of Texas Southwestern Medical School in Dallas, he joined the faculty of the UCSD Departments of Medicine and Cardiology and the Center for Molecular Genetics. Subsequently, Dr. Chien became the Director of the UCSD Institute of Molecular Medicine and directed the joint UCSD-Salk Institute National Institutes of Health Molecular Medicine Training Program. Given his longstanding interest in training physician-scientists, he has served as an advisor/panel member of several private biomedical foundations, including the Doris Duke Charitable Foundation and the Wellcome Trust. He also has served as a senior consultant and board member to several biotechnology and large pharma over the past decade, fostering collaborative ties between academia and the private sector. His most recent accomplishments include the establishment of a new Institute of Molecular Medicine at Peking University, currently the premier site for cardiovascular science and medicine in China. He has received several awards for his work, including the Pasarow Foundation Award and the Walter B. Cannon Award of the American Physiological Society.





# STEM CELL

M E E T I N G   O N   T H E   M E S A

The Frederic de Hoffmann Auditorium | The Salk Institute for Biological Studies  
Friday, November 7, 2008

## Program Overview

8:00 a.m. . . . . Opening Remarks  
8:30 - 9:15 a.m. . . . . Keynote Speech by Kenneth R. Chien, M.D., Ph.D.  
9:15 - 10:30 a.m. . . . . Cardiovascular – Panel 1  
10:30 - 10:45 a.m. . . . . Morning Break  
10:45 a.m. - Noon . . . . . Neurodegenerative – Panel 2  
Noon - 12:15 p.m. . . . . A Special Address by Alan Trounson, Ph.D,  
President, California Institute for Regenerative Medicine  
12:15 - 1:00 p.m. . . . . Lunch  
1:00 - 2:15 p.m. . . . . Diabetes – Panel 3  
2:15 - 2:30 p.m. . . . . Afternoon Break  
2:30 - 3:45 p.m. . . . . Cancer – Panel 4  
3:00 - 5:00 p.m. . . . . Poster Viewing Session open to the public  
(parallel to the panel sessions)  
3:45 - 5:00 p.m. . . . . Industry Wrap-up – Panel 5  
5:00 - 7:00 p.m. . . . . Poster Session and Networking Cocktail Reception




Sanford Consortium  
FOR REGENERATIVE MEDICINE

*The Sanford Consortium for Regenerative Medicine combines the intellectual resources of four of the world's leading biomedical research institutions (UC San Diego,*

*Salk Institute for Biological Studies, Burnham Institute for Medical Research and The Scripps Research Institute) to pursue collaborative research projects that advance the search for breakthrough cures. The Sanford Consortium unites San Diego's brightest researchers to work side by side to harness the regenerative power of stem cells to diagnose, treat and cure degenerative diseases and injuries. The Sanford Consortium integrates the collective knowledge of these foremost biomedical research institutions, with the support of surrounding industry and local community, to create a global resource for stem cell research.*





## Cardiovascular – Panel 1

**Chair:** **Anthony DeMaria, M.D.**, Judith and Jack White Chair in Cardiology, Director, Sulpizio Family Cardiovascular Center, UC San Diego, School of Medicine, Editor, Journal of the American College of Cardiology

**Panel:** **Sylvia Evans, Ph.D.**, Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, and Department of Medicine, UC San Diego  
**Mark Mercola, Ph.D.**, Associate Director, Del E. Webb Neuroscience, Aging and Stem Cell Research Center, Professor, Burnham Institute for Regenerative Medicine  
**Joseph Wu, M.D., Ph.D.**, Assistant Professor, Cardiovascular Medicine, Stanford University, School of Medicine

### Cardiovascular Panel Sponsor



Histogen, Inc., is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment. Histogen has developed a rich product portfolio from one core technology process that fulfills market needs without the use of embryonic stem cells or animal products.

The purpose and focus of the company is on the research, development, manufacturing and sales of products derived from the company's core technology. Using this proprietary tissue-engineering platform, the company has created products that offer unique commercialization opportunities ranging from research tools to biological products in various markets and segments of the biomedical industry.

BioNuesis™ is a soluble all-human extracellular matrix kit, developed by Histogen, Inc. BioNuesis is intended for the adherence and expansion of cells in culture, including stem and progenitor cells, such as human ES cells. Many other cell types which require the ECM proteins laminin, fibronectin or collagen type IV can also be cultured with BioNuesis. The soluble human extracellular matrix proteins in BioNuesis provide an entirely human source of the ECM molecules laminin, fibronectin and collagen type IV, which have been shown to support human ES cell expansion, and which are also found in the murine tumor-derived ECM gels, such as MatriGel™. BioNuesis contains natural human laminin, fibronectin and collagen type IV in a ready-to-use format for cell culture applications.





## Cardiovascular – Panel 1

**Chair:** **Anthony DeMaria, M.D.**, Judith and Jack White Chair in Cardiology, Director, Sulpizio Family Cardiovascular Center, UC San Diego, School of Medicine, Editor, Journal of the American College of Cardiology

**Panel:** **Sylvia Evans, Ph.D.**, Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, and Department of Medicine, UC San Diego  
**Mark Mercola, Ph.D.**, Associate Director, Del E. Webb Neuroscience, Aging and Stem Cell Research Center, Professor, Burnham Institute for Regenerative Medicine  
**Joseph Wu, M.D., Ph.D.**, Assistant Professor, Cardiovascular Medicine, Stanford University, School of Medicine

### Cardiovascular Panel Sponsor




Histogen, Inc., is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment. Histogen has developed a rich product portfolio from one core technology process that fulfills market needs without the use of embryonic stem cells or animal products.

The purpose and focus of the company is on the research, development, manufacturing and sales of products derived from the company's core technology. Using this proprietary tissue-engineering platform, the company has created products that offer unique commercialization opportunities ranging from research tools to biological products in various markets and segments of the biomedical industry.

BioNuesis™ is a soluble all-human extracellular matrix kit, developed by Histogen, Inc. BioNuesis is intended for the adherence and expansion of cells in culture, including stem and progenitor cells, such as human ES cells. Many other cell types which require the ECM proteins laminin, fibronectin or collagen type IV can also be cultured with BioNuesis. The soluble human extracellular matrix proteins in BioNuesis provide an entirely human source of the ECM molecules laminin, fibronectin and collagen type IV, which have been shown to support human ES cell expansion, and which are also found in the murine tumor-derived ECM gels, such as MatriGel™. BioNuesis contains natural human laminin, fibronectin and collagen type IV in a ready-to-use format for cell culture applications.

- Chair:** **Floyd E. Bloom, M.D.**, Professor Emeritus, Molecular and Integrative Neuroscience Department, The Scripps Research Institute
- Panel:** **Larry Goldstein, Ph.D.**, Director, Stem Cell Program, Professor, Cellular and Molecular Medicine, UC San Diego  
**Kristin Baldwin, Ph.D.**, Assistant Professor, Department of Cell Biology, The Scripps Research Institute  
**Yi Eve Sun, Ph.D.**, Associate Professor, Department of Psychiatry and Biobehavioral Sciences, Department of Molecular and Medical Pharmacology, UC Los Angeles, David-Geffen School of Medicine

### Neurodegenerative Panel Sponsor



Applied Molecular Evolution (AME) is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME's principal focus has been on applying its proprietary AMEsystem™ technology platform

to the full range of protein therapeutic candidates including antibodies, cytokines, hormones and enzymes to develop novel human biotherapeutic candidates.

Since February 2004, AME has been a wholly-owned subsidiary of Eli Lilly and Company and is an integral part of Lilly's research organization.

Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

While geographically separate, AME works closely with Lilly colleagues in Indianapolis and around the world, sharing a corporate legacy of integrity and commitment to quality that spans more than a century.





## Diabetes – Panel 3

**Chair:** **Fred Levine, M.D., Ph.D.**, Professor and Director,  
Sanford Children's Health Research Center, Burnham Institute for Medical Research

**Panel:** **James Wells, Ph.D.**, Associate Professor, Division of Developmental Biology,  
University of Cincinnati, College of Medicine  
**Anil Bhushan, Ph.D.**, Assistant Professor, Department of Medicine and Molecular  
Biology Institute, UC Los Angeles, David-Geffen School of Medicine  
**Anne Bang, Ph.D.**, Associate Director, Stem Cell Technologies, Novocell, Inc.

### *Diabetes Panel Sponsor*

## JOHN MOORES

John Moores grew up in Texas, attending public schools in Corpus Christi and Houston. After high school he married, and worked full-

time as a computer programmer to support his young family. He has no formal education in computers or software development; he gained all of his knowledge and expertise on the job. He attended the University of Houston at night and received two degrees from that university, as well as an honorary Doctor of Humane Letters and the University of Houston's 1990 Distinguished Alumni Award.

In 1980, Moores founded BMC Software, Inc., as its sole shareholder and first programmer. He wrote the initial, highly successful software products at BMC and built BMC into a significant competitor in the computer software industry. Moores continues to be active in providing his creative talents for the development of computer software for many new start-up software companies.

In 1994, Moores purchased the San Diego Padres Baseball Club. Since his purchase of the team, the Padres have won four National League Western Division championships and one National League championship. Moores serves on Major League Baseball's Executive Council and on the board of directors of Major League Baseball Advanced Media.

Moores' professional life is complemented by his extensive humanitarian work. He has given much of his time and own personal wealth to a wide variety of causes around the globe. Of his many professional commitments, Moores has served on the University of California Board of Regents since 1999, as vice-chairman from 2001-2002 and chairman from 2002-2004; on the University of Houston System Board of Regents from 1991 to 1994; and on the Board of Trustees for The Scripps Research Institute since 1997, serving as Chairman since May 2006.

As Chairman of The Carter Center, Moores succeeded President Carter and is carrying on work that touches the lives of people in more than 65 countries, primarily in the poorest countries in sub-Saharan Africa, through its disease intervention, election monitoring, agriculture, public health training, mental illness advocacy, and civil and international conflict prevention programs.








**Chair:** **Inder Verma, Ph.D.**, Professor and American Cancer Society Professor, Laboratory of Genetics, Salk Institute for Biological Sciences

**Panel:** **Catriona Jamieson, M.D., Ph.D.**, Director, Stem Cell Research Program, Moores UC San Diego Cancer Center, Hematology Team Leader, Division of Hematology/Oncology and Assistant Professor of Medicine, UC San Diego  
**Hanna Mikkola, M.D., Ph.D.**, Assistant Professor Department of Molecular, Cell and Developmental Biology, UC Los Angeles

### Cancer Panel Sponsor



Stemgent moves stem cell science forward by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists and perfected in our laboratories. Stemgent's product offering has been specifically

optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, as well as cytokines, antibodies, transfection reagents, and more.

Stemgent actively licenses new products from leading stem cell laboratories. If you are interested in our product lines or would like to discuss licensing opportunities, visit [www.stemgent.com](http://www.stemgent.com) or call for more information.


## Industry Wrap-up – Panel 5



**Chair:** **Roger Bingham, Ph.D.**, Director, The Science Network

**Panel:** **Alan Trounson, Ph.D.**, President, California Institute for Regenerative Medicine  
**Zdenek Hostomsky, Ph.D.**, Executive Director, Research, Pfizer  
**Stephen Laderman, Ph.D.**, Senior Director, Molecular Tools, Agilent Technologies  
**Joydeep Goswami, Ph.D.**, Vice President and General Manager, Primary and Stem Cell Systems, Invitrogen





### Lead Sponsor



Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics and cell biology, as well as emerging fields such as stem cell science – placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,300 professionals and had revenues of more than \$1.15 billion in 2006.

For more information, visit [www.invitrogen.com](http://www.invitrogen.com) or [www.invitrogen.com/stemcell](http://www.invitrogen.com/stemcell).





## VIP Dinner Sponsor



Bell, Boyd & Lloyd employs a simple but powerful philosophy to help clients grow and prosper. We provide exceptional service for clients by using innovative legal strategies and sound legal judgment to achieve creative and cost-effective solutions. We build collaborative relationships with each client that focus on their goals.

We work with businesses of all sizes in the manufacturing, financial services and technology industries, service firms, government bodies, tax-exempt organizations and individuals. Our clients count on Bell, Boyd & Lloyd to help them through the most complicated legal challenges, as well as the day-to-day responsibilities of running a business.

Our clients know that whatever their legal needs may be, they have access to experienced and dedicated counsel at Bell, Boyd & Lloyd. Most importantly, our clients know our attorneys will work diligently to produce successful results while forming lasting relationships that are as valuable as the advice they receive.

We invite you to learn more about the strength of our practice areas and professionals. Contact us to put Bell, Boyd & Lloyd to work for you.

For more information, visit <http://www.bellboyd.com>.





### Webcast Sponsors



#### **Agilent Technologies**

Agilent Technologies is a leading provider of instrumentation, supplies, software and services to the life sciences. Agilent's 25,000+ customers range from global pharmaceutical corporations to biotech companies, government labs and academic researchers. With \$1.55 billion in revenue in fiscal year 2006, Agilent LSCA has approximately 4,000 employees worldwide and provides global sales, support and manufacturing. LSCA's major sites are in California, Delaware, Shanghai, Tokyo and Germany.

Agilent tools help scientists to understand complex biological processes, unlock the causes of disease and speed the discovery of new drugs. Agilent provides products throughout the entire pharmaceutical value chain from basic research to drug manufacturing quality control.

In the Life Science Markets, Agilent's products and services specifically address the needs of five key markets: genomics, proteomics, metabolomics, bioinformatics, and pharmaceutical analysis.

In Genomics research, Agilent's offering enables scientists to compare the gene activity of diseased versus healthy cells, providing insight into the genetic causes of disease. Agilent is a leading provider of microarray solutions and is particularly successful in supporting emerging genomic research techniques.

Bioinformatics enables scientists to pull together disparate sets of highly complex biological data and analyze the information. Agilent offers a range of informatics solutions spanning applications in gene expression, genotyping and protein identification. The GeneSpring family of bioinformatics systems is considered the industry's gold standard.

For more information, visit <http://www.agilent.com>



Pfizer is the world's largest research-based pharmaceutical company and is taking new approaches to better health. We discover and develop innovative medicines to treat and help prevent disease for both people and animals. Through consistent, high-quality manufacturing and distribution operations, our medicines reach patients in 180 nations. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support. At Pfizer, our colleagues work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.





Founded in 2000, the California Institute for Telecommunications and Information Technology (Calit2), a partnership between UC San Diego and UC Irvine,

houses over 1,000 researchers organized around more than 50 projects on the future of telecommunications and information technology and how these technologies will transform a range of applications important to the economy and citizens' quality of life. Calit2 brings together teams of faculty, student and staff researchers on both campuses with leading California telecommunications, computer, software, and applications companies. They conduct studies in "living laboratories" to investigate how the future Internet will accelerate advances in areas such as environmental science, civil infrastructure, intelligent transportation and telematics, genomic medicine, new media arts and digital cinema.

## Lunch Sponsors



Molecular Diagnostic Services, Inc. (MDS) is an independent contract service organization since 1992, providing comprehensive cellular and molecular biology, microbiology, sterility assurance, biocompatibility and toxicology services to pharmaceutical, biotechnology, medical

device, and research institutions.

We are prepared to serve as a non-GLP/GMP or strictly as a GLP/GMP contract resource for developed or pre-defined protocols for our national and international clients.

On the cutting edge of technology for 1.5 decades, MDS provides expert services in the fields of cellular and molecular biology, assay development, assay validation, cell identity, paternity, mutagenesis, in vitro toxicity, in vivo toxicity, as well as quality control services.

Our fundamental mission is helping our clients to maximize the return on their R&D investments. MDS also produces customized and specialty molecular biology reagents.

MDS provides prompt, comprehensive service to companies ranging from large international to small start-up firms. For some companies, we have become their in-house laboratory. Other clients use us to supplement their own capabilities-for special projects or to meet peak demand.

# JOHN MOORES

Please see Panel Sponsors.





### Networking Cocktail Reception Sponsor



**BioMED REALTY TRUST, INC.**  
Providing Real Estate to the Life Science Industry™

BioMed Realty Trust is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. Our tenants primarily include

biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry.

We currently own or have interests in 69 properties, which include 116 buildings with 10.4 million rentable square feet of life science and laboratory real estate, including approximately 1.9 million square feet of development in progress. We also own undeveloped land parcels adjacent to our existing properties that we estimate can support up to 1.4 million rentable square feet. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. We operate as a fully integrated, self-administered and self-managed REIT, providing management, leasing and development services to our properties.

Our mission is to create value for our shareholders and opportunities for our employees by being the leading provider of real estate to the life science industry. We are committed to building quality relationships, developing exceptional environments for our tenants, and contributing to the communities in which we work and live. We will succeed through integrity, trust and loyalty.

Our common stock trades on the New York Stock Exchange under the symbol "BMR." For more information, visit <http://www.biomedreality.com>.

### Media Sponsor

**THE WAITT FAMILY  
FOUNDATION**

HELPING GOOD PEOPLE DO GREAT THINGS



Established in 1993 by Ted Waitt, co-founder of Gateway, Inc., the initial scope of the Waitt Family Foundation was community building in at risk communities. After investing millions of dollars in

various programs in multiple communities, the foundation concluded that its work in domestic violence had the most measurable impact on those at risk today. It established The Waitt Institute for Violence Prevention in 2005 allowing the foundation to broaden its activities to exploring the past, and investing in science for the future. It then created The Waitt Institute for Discovery later in 2005 with a primary focus on Nautical Archaeology. Currently, in addition to funding its institutes, the foundation funds a variety of environmental and scientific programs with an emerging focus on ocean conservation.

For more information, visit <http://www.waittfoundation.org>.





CONNECT is a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Since 1985, CONNECT has assisted in the formation and development of over 1,000 companies and is widely regarded as the nation's most successful regional program linking inventors and entrepreneurs with the resources they need for success.

CONNECT programs are targeted toward inventors and entrepreneurs and are delivered with the assistance of its broad membership base in three major areas: new company creation, training and education, and recognition of the best in innovation.

Originally founded by the University of California, San Diego, CONNECT has a dual role in accelerating growth: it provides added value and delivers targeted, high-level expertise to San Diego's technology business community by teaming up with the region's most prominent industry-specific organizations and individuals, and by partnering with world-class UC San Diego resources, such as the School of Medicine, Jacobs School of Engineering, San Diego Super Computer Center, and the Scripps Research and Salk Institutes.

Please visit [www.connect.org](http://www.connect.org) for further information about CONNECT's mission, programs and events.




Imagine turning on your television—any time of day or night—and watching a heated debate about the impact of science on your life: from stem cell research and cloning to the use of genetically modified organisms (GMOs) in your food. From the biology of violence to the chemistry of addiction. From the puzzles of depression to the latest breakthroughs on aging. From the evolution of morality to the complexities of consciousness. From the exploration of space to the discovery of life beyond Earth.

Imagine eavesdropping on scientific meetings and Congressional hearings—getting the background buzz about science and its impact on social issues from education, ethics, and economics to law, psychology and religion.

Imagine a network that delivered the latest lecture by Stephen Hawking on the nature of time or by Jane Goodall on the chimpanzees of Gombe. Or archived footage of the





late Richard Feynman mesmerizing an audience with his Nobel-wattage intellect and irreverent humor. Perhaps you would find yourself in the midst of a marathon reprise of landmark television series like Carl Sagan's *Cosmos* or Jacob Bronowski's *The Ascent of Man*, rescued from retirement. Maybe a showing of *Life Story*, the dramatization of James Watson and Francis Crick's discovery of the double helix of DNA—or a *Nova* marathon. You might be taken into classrooms where America's star science teachers hold young minds spellbound with tales of our continuing odyssey to make sense of the natural world.

Put it all together and you have The Science Network (TSN). A C-SPAN for science. Visit [www.tsntv.org](http://www.tsntv.org) for further information.



BIOCOM is the largest regional life science association in the world, representing more than 575 member companies in Southern California. The association focuses on initiatives that positively influence the region's life science community in the development and delivery of innovative products that improve health and quality of life. This includes initiatives in public policy, capital formation, workforce development, group purchasing and member services such as networking events. BIOCOM is ultimately a place where the regional life sciences community can come together, make connections, and work together as a united force to ensure growth and viability.

BIOCOM is consistently working to keep its members abreast of current trends and issues impacting their business as well as expanding members' professional network through our more than 100 networking opportunities annually. It is via these events that we are able to provide a supportive environment to facilitate technology convergence that will assist our medical device, diagnostic, biotechnology and pharmaceutical member companies to continually increase their technology synergies to fill their pipeline.

Get your company connected and contact us today.

For more information, visit <http://www.biocom.org>.



Thank you to those who have  
contributed time and energy  
to make this day possible.

**Roger Bingham, Ph.D.,** Director, The Science Network

**Floyd E. Bloom, M.D.,** Professor Emeritus,  
Molecular and Integrative Neuroscience Department,  
The Scripps Research Institute

**Jennifer Braswell, Ph.D.,** Stem Cell Program Administrator,  
UC San Diego

**Phil Douglass, Ph.D.,** Product Specialist, Genomic  
Applications, Agilent Technologies

**Joydeep Goswami, Ph.D.,** Vice President and General  
Manager, Primary and Stem Cell Systems, Invitrogen

**Juan Carlos Izpisua Belmonte, Ph.D.,** Professor, Gene  
Expression Laboratory, Salk Institute for Biological  
Sciences

**Catriona Jamieson, M.D., Ph.D.,** Director, Stem Cell  
Research Program, Moores UC San Diego Cancer  
Center, Hematology Team Leader, Division of  
Hematology/Oncology and Assistant Professor of  
Medicine, UC San Diego

**Leanne Jones, Ph.D.,** Assistant Professor, William  
Scandling Developmental Chair, Laboratory of  
Genetics, Salk Institute for Biological Sciences

**Alan J. Lewis, Ph.D.,** President and CEO, Novocell

**Michael Nunn, Ph.D.,** Director of Grants Development,  
Salk Institute for Biological Sciences

**Duane Roth,** CEO, CONNECT

**Evan Snyder, M.D., Ph.D.,** Program Director, Professor,  
Stem Cells and Regenerative Medicine, The Burnham  
Institute for Regenerative Medicine

**Gene Yeo, Ph.D.,** Assistant Professor, Department of  
Cellular and Molecular Medicine, University of  
California, San Diego





# 3rd Annual Stem Cell Meeting on the Mesa

Presented by





In Partnership with



Lead Sponsor



Supporting Sponsors



JOHN MOORES



THE WAITT FAMILY  
FOUNDATION  
HELPING GOOD PEOPLE DO GREAT THINGS



STEM CELL  
MEETING ON THE MESA

Sanford Consortium for Regenerative Medicine  
P.O. Box 6930, San Diego, CA 92166-6930